

Title (en)
ANTI-HER2 ANTIBODIES AND COMPOSITIONS

Title (de)
ANTIKÖRPER UND ZUSAMMENSETZUNGEN GEGEN HER2

Title (fr)
ANTICORPS ET COMPOSITIONS ANTI-HER2

Publication
EP 2542589 A4 20130807 (EN)

Application
EP 11750275 A 20110303

Priority

- US 31055210 P 20100304
- DK PA201070085 A 20100304
- US 35413310 P 20100611
- US 201061428014 P 20101229
- IB 2011050903 W 20110303

Abstract (en)
[origin: WO2011107957A1] The present invention relates to novel therapeutic antibodies directed against HER2 (ErbB2), as well as recombinant polyclonal anti-HER2 antibody compositions, and use of the antibodies and antibody composition for treatment of cancers. The antibody composition comprises at least three recombinant antibodies that bind distinct epitopes of HER2. Two of the antibodies bind to HER2 on the surface of a cell such that they generate a cross-linked antibody-receptor lattice on the cell surface and thereby result in HER2 receptor internalization. The third antibody in the composition binds HER2 such that it blocks heterodimerization between HER2 and HER3.

IPC 8 full level
C07K 16/30 (2006.01); **A61K 39/00** (2006.01)

CPC (source: EP)
A61P 35/00 (2017.12); **C07K 16/32** (2013.01); **A61K 2039/507** (2013.01); **C07K 2317/30** (2013.01); **C07K 2317/73** (2013.01); **C07K 2317/732** (2013.01); **C07K 2317/734** (2013.01); **C07K 2317/76** (2013.01); **C07K 2317/77** (2013.01)

Citation (search report)

- [Y] WO 2004048525 A2 20040610 - GENENTECH INC [US]
- [YP] WO 2010022736 A2 20100304 - SYMPHOGEN AS [DK], et al
- [I] NAHTA R ET AL: "The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 64, no. 7, 1 April 2004 (2004-04-01), pages 2343 - 2346, XP002378994, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-03-3856
- [Y] COYNE C P ET AL: "Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition", JOURNAL OF DRUG TARGETING, HARWOOD ACADEMIC PUBLISHERS GMBH, DE, vol. 17, no. 6, 1 July 2009 (2009-07-01), pages 474 - 489, XP008149521, ISSN: 1061-186X, DOI: 10.1080/10611860903012802
- [YP] HUHALOV ALEXANDRA ET AL: "MM-111, an ErbB2/ErbB3 bispecific antibody with potent activity in ErbB2-overexpressing cells, positively combines with trastuzumab to inhibit growth of breast cancer cells driven by the ErbB2/ErbB3 oncogenic unit", AMERICAN ASSOCIATION FOR CANCER RESEARCH. PROCEEDINGS OF THE ANNUAL MEETING, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 51, 1 April 2010 (2010-04-01), pages 845 - 846, XP009145436, ISSN: 0197-016X
- See references of WO 2011107957A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2011107957 A1 20110909; CN 102884084 A 20130116; CN 102884084 B 20161207; EP 2542589 A1 20130109; EP 2542589 A4 20130807; JP 2013520984 A 20130610; JP 6039428 B2 20161207; TW 201141519 A 20111201

DOCDB simple family (application)
IB 2011050903 W 20110303; CN 201180022307 A 20110303; EP 11750275 A 20110303; JP 2012555532 A 20110303; TW 100107086 A 20110303